Patent CA1108058A successfully refreshed from Google Patents.
CA1108058A
Expired / Lapsed
CA
⏱️ 0.0 years remaining
Blood preservation by polymer releasing phosphate
Assignee: Research Corp
•
Filing: 1978-06-07
•
Granted: 1981-09-01
•
Expires: 1998-06-07
Abstract
Abstract ABSTRACT OF THE DISCLOSURE The useful shelf life of living erythrocytes suitable for trans-fusion is extended by maintaining adequate ATP and 2,3 DPG levels using a water insoluble polymer containing releaseable phosphate ions as a source of inorganic phosphate ions during the storage period for supplying physiologically acceptable, continuous sustained release of metabolizable phosphate to such erythrocyte. This maintains the ATP and the 2,3 levels at least equal to those of freshly drawn blood for a storage period equivalent to 28 days of storage at 4°C.
Inventors
- 👤 Denise M. Harmening
Bibliographic Details
Application Number
—
Jurisdiction
CA
Data Source
google_patents
Last Synchronized
2026-11-03 16:42
CPC Classifications
A; A61; A61K; A61K35/00; A61K35/12; A61K35/14; A61K35/16; A01; A01N; A01N1/00; A01N1/10; A01N1/12; A01N1/122; A01N1/126; A61K35/18
Claims Analysis
Total Claims: 28
Claim 1
Independent Claim
78 words
In a composition of matter comprising metabolizing erythro-cytes in an in vitro environment capable of supporting erythrocyte metabol-ism, the improvement which comprises a water insoluble polymer containing releaseable phosphate ions for supplying a physiologically acceptable, con-tinuous, sustained release source of metabolizable phosphate to said erythrocytes in an amount sufficient to maintain both 2,3 DPG and ATP levels at least equal to those of freshly drawn blood for a storage period equivalent to 28 days of storage at 4°C.
Claim 2
Dependent Claim
78 words
In a composition of matter comprising metabolizing erythro-cytes in an in vitro environment capable of supporting erythrocyte metabol-ism, the improvement which comprises a water insoluble polymer containing releaseable phosphate ions for supplying a physiologically acceptable, con-tinuous, sustained release source of metabolizable phosphate to said erythrocytes in an amount sufficient to maintain both 2,3 DPG and ATP levels at least equal to those of freshly drawn blood for a storage period equivalent to 28 days of storage at 4°C.
Claim 3
Dependent Claim
18 words
A composition according to Claim 1, wherein said environment includes a safe and effective amount of an anticoagulant.
Claim 4
Dependent Claim
17 words
A composition according to Claim 2, wherein said environment includes packed blood cells substantially free of plasma.
Claim 5
Dependent Claim
12 words
A composition according to Claim 2, wherein said environment includes whole blood.
Claim 6
Dependent Claim
11 words
A composition according to Claim 2, wherein said anticoagulant is citrate-phosphate-dextrose.
Claim 7
Dependent Claim
12 words
A composition according to Claim 1, wherein said water-in-soluble polymer is particulate.
Claim 8
Dependent Claim
14 words
A composition according to Claim 6, wherein said polymer is an ion exchange resin.
Claim 9
Dependent Claim
16 words
A composition according to Claim 7, wherein said polymer is a weakly basic anion exchange resin.
Claim 10
Dependent Claim
15 words
A composition according to Claim 8, wherein said metabolizable phosphate is inorganic dibasic phosphate HPO=.
Claim 11
Dependent Claim
17 words
A composition according to Claim 8, wherein said environment includes a safe and effective amount of anticoagulant.
Claim 12
Dependent Claim
12 words
A composition according to Claim 10, wherein said erythrocytes are human erythrocytes.
Claim 13
Dependent Claim
11 words
A composition according to Claim 11, wherein said anticoagu-lant is citrate-phosphate-dextrose.
Claim 14
Dependent Claim
18 words
A composition according to Claim 10, wherein said in vitro environment is within a sterile blood collection container.
Claim 15
Dependent Claim
83 words
In an article of manufacture comprising a sterile blood col-lection and storage container having a safe and effective amount of anti-coagulant therein, the improvement which comprises a water insoluble polymer containing releaseable phosphate ions for supplying a continuous, sustained release source of metabolizable phosphate to metabolizing erythrocytes in an amount sufficient to maintain both 2,3 DPG and ATP levels of collected blood at least equal to those of freshly drawn blood for a storage period equivalent to 28 days of storage at 4°C.
Claim 16
Dependent Claim
83 words
In an article of manufacture comprising a sterile blood col-lection and storage container having a safe and effective amount of anti-coagulant therein, the improvement which comprises a water insoluble polymer containing releaseable phosphate ions for supplying a continuous, sustained release source of metabolizable phosphate to metabolizing erythrocytes in an amount sufficient to maintain both 2,3 DPG and ATP levels of collected blood at least equal to those of freshly drawn blood for a storage period equivalent to 28 days of storage at 4°C.
Claim 17
Dependent Claim
12 words
An article according to Claim 14, wherein said water-insoluble polymer is particulate.
Claim 18
Dependent Claim
14 words
An article according to Claim 15, wherein said polymer is an ion exchange resin.
Claim 19
Dependent Claim
16 words
An article according to Claim 16, wherein said polymer is a weakly basic anion exchange resin.
Claim 20
Dependent Claim
75 words
In a method for maintaining metabolizing erythrocytes suita-ble for transfusion in a sterile container, the improvement which comprises adding to said container a water insoluble polymer containing releaseable phosphate ions for supplying a continuous source of metabolizable phosphate to said metabolizing erythrocytes in an amount sufficient to maintain both 2,3 DPG and ATP levels at least equal to those of freshly drawn blood for a storage period equivalent to 28 days of storage at 4°C.
Claim 21
Dependent Claim
75 words
In a method for maintaining metabolizing erythrocytes suita-ble for transfusion in a sterile container, the improvement which comprises adding to said container a water insoluble polymer containing releaseable phosphate ions for supplying a continuous source of metabolizable phosphate to said metabolizing erythrocytes in an amount sufficient to maintain both 2,3 DPG and ATP levels at least equal to those of freshly drawn blood for a storage period equivalent to 28 days of storage at 4°C.
Claim 22
Dependent Claim
12 words
A method according to Claim 18, wherein said water-insoluble polymer is particulate.
Claim 23
Dependent Claim
14 words
A method according to Claim 19, wherein said polymer is an ion exchange resin.
Claim 24
Dependent Claim
16 words
A method according to Claim 20, wherein said polymer is a weak-ly basic anion exchange resin.
Claim 25
Dependent Claim
39 words
A storable, transfusable composition of matter comprising metabolizing erythrocytes in an in vitro environment capable of supporting erythrocyte metabolism having incorporated therein a water insoluble polymer containing releaseable phosphate ions capable of continuously supplying metabolizable phosphate to said erythrocytes.
Claim 26
Dependent Claim
39 words
A storable, transfusable composition of matter comprising metabolizing erythrocytes in an in vitro environment capable of supporting erythrocyte metabolism having incorporated therein a water insoluble polymer containing releaseable phosphate ions capable of continuously supplying metabolizable phosphate to said erythrocytes.
Claim 27
Dependent Claim
13 words
23, A composition according to Claim 22, wherein said water-in-soluble polymer is particulate.
Claim 28
Dependent Claim
14 words
A composition according to Claim 23, wherein said polymer is an ion exchange resin.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.